Speaker Profile
Ph.D., Chief Technology Advisor, CellMax Life
Biography
John J Sninsky, Ph. D. is Chief Technology Advisor for Cell Max Life. John has a deep understanding of the underlying biology of colon cancer progression that provides mechanistic insights of biomarkers for blood-based screening. He has an extensive knowledge of the development and application of pioneering molecular procedures and bioinformatics for the translation of research-grade biomarker assays into clinical-grade broadly adopted diagnostic tests as well as diagnostic tests paired with pharmacotherapies. John is the author of more than 125 scientific papers. He was a member of teams that developed the Polymerase Chain Reaction, sequenced the Human Genome and developed clinical-grade DNA and RNA liquid biopsies. John spent 30 years in senior management at companies that ranged from small to enterprise CLIA-CAP laboratories and in vitro diagnostic companies that commercialize FDA clearedapproved IVD kits. These companies included Cetus, Roche Molecular Systems, Celera Diagnostics, Quest Diagnostics, Molecular Stethoscope and Care Dx.
Talk
Profound advances in our understanding of the natural history of cancer have occurred over the last decade. Removal of advanced adenomas makes the greatest contribution to reduction in CRC morbidity, mortality and cost. The complexity of the adenoma-carcinoma continuum requires an accurate blood-based multimodal technology CRC screening test.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Daniel De Carvalho, University of Toronto
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Stephen Master, CHOP/U Penn
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Minetta Liu, Natera
• Rita Shaknovich, Agilent
• Ajay Gannerkote, Integrated DNA Tech
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Eric Klein, GRAIL
• Sarah Moseley, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Ron Andrews, Dxcover
• Pankaj Vats, NVIDIA
• Paul Shi, Amgen
• Christopher Troll, Claret Bioscience
Integrating Genetic Risk with Early Detection: A Precision Prevention Framework for Cardiovascular Disease
• Paolo Di Domenico, Allelica
AI-Driven Metagenomic and Host RNA Profiling for Precision Diagnosis of Infections
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA: Bridging Infection Biology and Early Diagnostics
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection: AI-Driven Signal Profiling
• John Sninsky, CellMax Life
Overcoming Limits of Traditional cfDNA Assays Using Active Chromatin
• Diana Abdueva, Aqtual
Whole-genome methylome-based early cancer signal detection
• Sally Mackenzie, EpiMethyl Analytics
BrainSee Sees the Brain: FDA-Approved AI for Predicting Modifiable Risk of Developing Alzheimer’s Within Five Year
• Padideh Kamali-Zare, Darmiyan
